Shane Climie, Ph.D.
I have more than 20 years of R&D and business development experience in the life sciences and pharmaceutical industry. I’ve led research teams involved in all aspects of drug discovery and have designed, negotiated and managed many R&D collaborations. I also have extensive experience in technology evaluation, technology development, and strategic planning.
Before joining Popper and Company, I held several positions at Protana Inc. (formerly MDS Proteomics), ranging from SVP, Science Strategy and Business Development to SVP, Research Collaborations, and was co-founder, Vice President and Chief Technology Officer of MDS Ocata. In 1999 I served as a Visiting Research Scientist at the Samuel Lunenfeld Research Institute. From 1990 to 1999, I held several positions at Allelix Biopharmaceuticals, Inc. (now NPS Allelix Inc., Nasdaq:NPSP), including Principal Scientist, Manager of New Technologies, and Manager of Molecular and Structural Biology.
I was a postdoctoral scholar at the University of California at San Francisco, received a Ph.D. in medical biophysics from the University of Toronto, and hold a B.Sc. in biology from the University of Waterloo.
Being a member of the Popper and Company team has enabled me to work with my colleagues on a wide range of multidisciplinary projects that rely on my expertise and interest in “-omics” technologies, molecular biology, drug discovery, strategic planning, and health care in general.